Breast cancer

Summary

The Breast Cancer research group aims to better understand breast cancer development, the origin of disease subtypes, and disease progression and vulnerabilities. The research projects comprise the major disease subtypes as well as BRCA1/2-mutant breast cancer. The group also works to develop novel targeted preventive approaches and to improve the quality of life of patients. This is a multidisciplinary team that combines the experience and knowledge of clinical and translational researchers.

320 Publications

Strategic lines

Selected Publications

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690.

Langille E, Al Zahrani KN, Ma Z, Liang M, Uuskula Reimand L, Espin R, Teng K, Malik A, Bergholtz H, El Ghamrasni S, Afiuni Zadeh S, Tsai R, Alvi S, Elia A, Lu Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sorlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis and promotes breast cancer. Cancer Discov. 2022;doi:10.1158/2159-8290.CD-21-0865.

Mateo F, He Z, Mei L, de Garibay GR, Herranz C, García N, Lorentzian A, Baiges A, Blommaert E, Gómez A, Mirallas O, Garrido Utrilla A, Palomero L, Espín R, Extremera AI, Soler Monsó MT, Petit A, Li R, Brunet J, Chen K, Tan S, Eaves CJ, McCloskey C, Hakem R, Khokha R, Lange PF, Lázaro C, Maxwell CA, Pujana MA. Modification of BRCA1-associated breast cancer risk by HMMR overexpression. Nat. Commun. 2022;13(1):1895-1895. doi:10.1038/s41467-022-29335-z.

He Z, Ghorayeb R, Tan S, Chen K, Lorentzian AC, Bottyan J, Aalam SMM, Pujana MA, Lange PF, Kannan N, Eaves CJ, Maxwell CA. Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation. Nat. Commun. 2022;13(1):2200-2200. doi:10.1038/s41467-022-29885-2.

Guix I, Liu Q, Pujana MA, Ha P, Piulats J, Linares I, Guedea F, Mao JH, Lazar A, Chapman J, Yom SS, Ashworth A, Barcellos Hoff MH. Validation of anti-correlated TGFß signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy. Clin. Cancer Res. 2022;28(7):1372-1382. doi:10.1158/1078-0432.CCR-21-2846.

Selected Projects

LCX21020. Becas de posdoctorado Junior Leader Incoming. FUNDACIÓ "LA CAIXA". Budget: 297900. 2022-2025. PI: Pujana PUJANA, Miguel Ángel.

19FIS022. Atlas de moduladores moleculares del cáncer y validación en el subtipo receptor estrógenopositivo de cáncer de mama. Instituto de Salud Carlos III (ISCIII). Budget: 233832,5. 2019-2022. PI: Pujana PUJANA, Miguel Ángel.

FIS21092. BASE BIOLÓGICA DE LA MODIFICACIÓN DEL RIESGO DE CÁNCER DE MAMA: HACIA LA MEJORA DE LA PREVENCIÓN. Instituto de Salud Carlos III (ISCIII). Budget: 196020. 2022-2024. PI: Pujana PUJANA, Miguel Ángel.

20ACL092. ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO (1:1), DOBLE CIEGO, CONTROLADO CON PLACEBO, DE DOS PARTES PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ALPELISIB (BYL719) EN COMBINACIÓN CON TRASTUZUMAB Y PERTUZUMAB COMO TERAPIA DE MANTENIMIENTO EN PACIENTES CON CÁNCER DE MAMA AVANZADO HER2 POSITIVO CON UNA MUTACIÓN DE PIK3CA. Novartis Farmacéutica, S.A.. Budget: 152413,02. 2020- . PI: Pernas Simón, Sonia.

21ACL065. TENACIDAD: UN ESTUDIO DE FASE 2, MULTICÉNTRICO, ABIERTO, DE BRAZO ÚNICO SOBRE LA MONOTERAPIA DE AL101 EN PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO CON ACTIVACIÓN DE NOTCH. PRECISION FOR MEDICINE, LLC. Budget: 123322,3. 2021- . PI: Pernas Simón, Sonia.

Technology transfer

More Information

The group has extensive experience in bioinformatic and systems biology approaches, combined with in vitro and in vivo experimental studies, aimed at better understanding the development and progression of breast cancer. Over the past five years, the team has published 50 articles on a regular basis, including various manuscripts in leading journals. The team has also received various national and international grants and has established strong collaborations with national and international leaders in the area.